Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled tigecycline offers the possibility of treating M. abscessus with significantly reduced side effects compared to IV tigecycline.
PureIMS CEO Bram van Dijck commented, “We are very excited to work on this promising research and development project in offering a treatment for patients suffering from NTM pulmonary disease, a true unmet medical need. The combined knowledge and expertise of the consortium will be very beneficial in carrying this project forward. PureIMS will start the feasibility work for inhaled tigecycline using its proprietary dry powder inhaler Cyclops and we expect to have initial results on the technical feasibility before the end of 2022.”
PureIMS is already developing several antibiotic DPIs for the treatment of lung infections that are based on the Cyclops device, including amikacin for the treatment of tuberculosis and tobramycin and colistin for cystic fibrosis.
Radboudumc Head of Mycobacteriology Jakko van Ingen said, “The initial target of our partnership will be to set up the required studies, up to phase 2 and 3. This partnership and inhaled tigecycline have the capacity to finally develop effective treatments for this severe emerging infection.”
Sever Pharma Solutions Site Manager Guido van der Aar added, “Sever Pharma Solutions participates in collaborations like these, with the objective to make them available through registration and affordable prices. These inventions need to make it to the market, to become readily available for patients suffering from NTM pulmonary disease.”
Read the PureIMS press release.
